US biopharma essentials could get paddled in ugly lame duck session
This article was originally published in SRA
While Congress managed to pass a continuing resolution at the last hour to keep the US federal government running six more months, it adjourned at the end of last week leaving critical business unfinished until after the November elections, most notably, preventing the $1.2 trillion across-the-board sequestration spending cuts from kicking in come January1-3.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.